Factor This Power Engineering
Live Events
DTECH® Events
POWERGEN™
INFOCAST Events
Calendar
Webinars
Podcasts
Factor This
This Week in Cleantech
Factor This Policycast
Contribute Content
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Smart Grids
Transmission
Hydropower
Dams & Civil Structures
Small Hydropower
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Project Development
Tariffs
Electric Vehicles
EV Charging
Vehicle to Grid
Subscribe
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Transmission
Smart Grids
Hydropower
Dams & Civil Structures
Small Hydro
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Electric Vehicles
EV Charging
Vehicle to Grid
Factor This: Power Engineering
Live Events
DISTRIBUTECH®
POWERGEN™
INFOCAST Events
Podcasts
Factor This
Factor This Policycast
This Week in Cleantech
Webinars
Calendar
Contribute Content
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Pharvaris N.V.
< Previous
1
2
3
Next >
Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks
January 22, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities
January 05, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023
December 08, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Announces Pricing of $300 Million Underwritten Offering of Ordinary Shares and Pre-funded Warrants
December 06, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks
December 06, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris to Present at the GA²LEN UCARE Conference 2023
November 30, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations Officer
November 15, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific Meeting
November 09, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Reports Third Quarter 2023 Financial Results and Provides Business Update
November 02, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris To Present at the ACAAI 2023 Annual Scientific Meeting
October 30, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris To Present at the APAAACI 2023 International Conference
October 13, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris To Present at the CIIC Fall 2023 Conference
October 04, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris To Participate in the 2023 Cantor Global Healthcare Conference
September 19, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris To Present at the 18th German Allergy Congress
September 06, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris To Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
September 06, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris To Present at the 2023 HAEi Regional Conference EMEA
August 23, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Reports Second Quarter 2023 Financial Results and Provides Business Update
August 07, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Presents Clinical Data at the 2023 U.S. HAEA National Summit
July 21, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Announces FDA Removal of Clinical Hold of Deucrictibant for the On-Demand Treatment of HAE
June 26, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Announces $70 Million Private Placement Financing
June 20, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Data of Deucrictibant for the On-Demand Treatment of HAE Attacks Presented at the EAACI Congress 2023
June 10, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Announces Annual Meeting of Shareholders
June 01, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Reports First Quarter 2023 Financial Results and Provides Business Update
May 08, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Deucrictibant Data Highlighted in Multiple Presentations at the C1-Inhibitor Deficiency and Angioedema Workshop
May 06, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
April 05, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks Highlighted at the 2023 HAEi Regional Conference APAC
March 18, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris to Present in Upcoming March Investor Conferences
March 02, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris to Highlight Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks at AAAAI Annual Meeting
February 24, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris to Present at SVB Securities Global Biopharma Conference
February 08, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Provides Regulatory, Clinical, and Corporate Updates
January 09, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
